AngioDynamics, Inc.  

(Public, NASDAQ:ANGO)   Watch this stock  
Find more results for David A. Donnelly, Jr.�
-0.04 (-0.26%)
Jul 29 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 15.28 - 15.53
52 week 13.13 - 19.80
Open 15.33
Vol / Avg. 87,223.00/134,401.00
Mkt cap 547.78M
P/E     -
Div/yield     -
EPS -0.12
Shares 35.92M
Beta 0.92
Inst. own 96%
Oct 7, 2015
Q1 2016 AngioDynamics Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Jul 16, 2015
Q4 2015 AngioDynamics Inc Earnings Call - Webcast
Jul 16, 2015
Q4 2015 AngioDynamics Inc Earnings Release
Jun 1, 2015
AngioDynamics Inc at Jefferies Global Healthcare Conference
May 18, 2015
AngioDynamics Inc at UBS Global Healthcare Conference
May 14, 2015
AngioDynamics Inc at Bank of America Merrill Lynch Health Care Conference
More events from DailyFinance »    

Key stats and ratios

Q1 (Feb '15) 2014
Net profit margin -4.92% 0.75%
Operating margin -11.72% 3.65%
EBITD margin - 14.63%
Return on average assets -2.16% 0.34%
Return on average equity -3.14% 0.50%
Employees 1,300 -
CDP Score - -


14 Plaza Dr
LATHAM, NY 12110-2166
United States - Map
+1-518-7981215 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


AngioDynamics, Inc. is engaged in designing, manufacturing and selling a range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease and for use in oncology and surgical settings. The Company's devices are used in minimally invasive, image-guided procedures. The Company’s product offerings fall within three product groupings: Peripheral Vascular, Vascular Access and Oncology/Surgery. The Company’s Peripheral Vascular products include Fluid Management, Venous, Thrombus Management, Angiographic, as well as other products. Image-guided vascular access, or IGVA, involves the use of advanced imaging equipment to guide the placement of catheters that deliver short-term drug therapies into the central venous system. The Company’s Oncology/Surgery product offerings include Microwave Ablation products, Radiofrequency Ablation (RFA) and NanoKnife product lines.

Officers and directors

Howard W. Donnelly Independent Chairman of the Board
Age: 53
Bio & Compensation  - Reuters
Joseph M. DeVivo President, Chief Executive Officer, Director
Age: 47
Bio & Compensation  - Reuters
Mark T. Frost Chief Financial Officer, Executive Vice President
Age: 51
Bio & Compensation  - Reuters
John J. Soto Executive Vice President, Chief Commercial Officer
Age: 50
Bio & Compensation  - Reuters
Matthew Kapusta Senior Vice President - Business Development
Age: 42
Bio & Compensation  - Reuters
Mark A. Stephens Senior Vice President - Administration
Age: 46
Bio & Compensation  - Reuters
Stephen A. Trowbridge Senior Vice President, General Counsel
Age: 40
Bio & Compensation  - Reuters
David F. Burgstahler Independent Director
Age: 47
Bio & Compensation  - Reuters
Jeffrey G. Gold Independent Director
Age: 66
Bio & Compensation  - Reuters
Kevin J. Gould Independent Director
Age: 60
Bio & Compensation  - Reuters